Global Human Coagulation Factor VIII Supply, Demand and Key Producers, 2026-2032

The global Human Coagulation Factor VIII market size is expected to reach $ 18990 million by 2032, rising at a market growth of 6.2% CAGR during the forecast period (2026-2032).

Human Coagulation Factor VIII is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene results in hemophilia A. Human Coagulation Factor VIII concentrated from donated blood plasma (Aafact or Alphanate, Monoclate-P®), or alternatively recombinant Human Coagulation Factor VIII can be given to hemophiliacs to restore hemostasis.

Market Drivers:

The increasing prevalence of hemophilia A is a key driver for the Human Coagulation Factor VIII market. As awareness and diagnosis rates improve, more patients are receiving proper treatment, driving demand for Factor VIII therapies. Additionally, advancements in biotechnology, including the development of recombinant and extended half-life Factor VIII products, have significantly improved treatment efficacy and patient convenience. Government initiatives and healthcare programs supporting rare disease treatments, along with expanded access to hemophilia care in developing regions, further boost market growth. The rise of gene therapy research also presents potential future opportunities for transforming the hemophilia treatment landscape.

Market Challenges:

Despite strong market growth, several challenges persist, including the high cost of Factor VIII therapies, which limits affordability and accessibility for many patients, especially in low-income regions. Additionally, plasma-derived Factor VIII products face supply chain constraints due to reliance on blood donations. Another major challenge is the development of inhibitors (antibodies) in some patients, which can render Factor VIII treatment ineffective and necessitate alternative therapies. Regulatory complexities and the need for stringent quality control in manufacturing also pose barriers for new entrants in the market.

This report studies the global Human Coagulation Factor VIII production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Human Coagulation Factor VIII and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Human Coagulation Factor VIII that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Human Coagulation Factor VIII total production and demand, 2021-2032, (K Bottles)

Global Human Coagulation Factor VIII total production value, 2021-2032, (USD Million)

Global Human Coagulation Factor VIII production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Bottles), (based on production site)

Global Human Coagulation Factor VIII consumption by region & country, CAGR, 2021-2032 & (K Bottles)

U.S. VS China: Human Coagulation Factor VIII domestic production, consumption, key domestic manufacturers and share

Global Human Coagulation Factor VIII production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Bottles)

Global Human Coagulation Factor VIII production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Bottles)

Global Human Coagulation Factor VIII production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Bottles)

This report profiles key players in the global Human Coagulation Factor VIII market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Takeda, Bayer, CSL, Pfizer, Grifols, Biogen, Octapharma, NovoNordisk, Greencross, Kedrion, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Human Coagulation Factor VIII market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Bottles) and average price (USD/Bottle) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global Human Coagulation Factor VIII Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Human Coagulation Factor VIII Market, Segmentation by Type:
Recombinant Factor VIII
Plasma-derived Factor VIII

Global Human Coagulation Factor VIII Market, Segmentation by Application:
Hemophilia A
Spontanous / Trauma
Surgical
Other

Companies Profiled:
Takeda
Bayer
CSL
Pfizer
Grifols
Biogen
Octapharma
NovoNordisk
Greencross
Kedrion
BPL
Hualan Bio
RAAS
SinoCellTech
Taibang Bio
Huarun Boya
Shuanglin Bio
Yuandashuyang
Weiguang Bio

Key Questions Answered:

1. How big is the global Human Coagulation Factor VIII market?

2. What is the demand of the global Human Coagulation Factor VIII market?

3. What is the year over year growth of the global Human Coagulation Factor VIII market?

4. What is the production and production value of the global Human Coagulation Factor VIII market?

5. Who are the key producers in the global Human Coagulation Factor VIII market?

6. What are the growth factors driving the market demand? Show more